(PharmaNewsWire.Com, August 02, 2017 ) According to a precise analysis, there are 32.6 million people living with any type of cancer within the five years of diagnosis. The cancer type is generally incurable once they progress to the stage where they are unresectable, making Oncology an important part of medical science. To discuss the robust growth of the oncology market, Market Research Hub (MRH) has recently added a detailed study titled as “Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors” to its vast report repository. It is analyzed that the global revenue for the oncology market is forecast to grow at a compound annual growth rate (CAGR) of 10.66% from $118.6 billion in 2016 to $241.0 billion in 2023.
Oncology, a branch of medicine which deals with the prevention, diagnosis, and treatment of cancer. When diagnosed early, it can prevent the death of millions of people around the globe. The report analyzes the oncology pipeline and stratifies by stage of development, molecule type, and molecular target, with a granular breakdown across key indications. It discusses the most popular types of molecule type and molecular target in the pipeline. The researched therapeutic study initiated with the introduction of the therapy area, symptoms, diagnosis, etiology and pathophysiology of the cancer type. The report further discusses the epidemiology patterns by prevalence, patient segmentation, and diagnostic & treatment usage rates. Patient segmentation includes breast cancer, colorectal cancer, lung cancer, prostate cancer and hematological cancers.
Moreover, the prognosis discussed includes diagnosis of breast cancer, colorectal cancer, non-small-cell lung cancer and prostate cancer. Finally, the treatment of the cancer is detailed that vary from surgery & radiation therapy, chemotherapy, hormonal therapies and targeted therapies.
The therapeutic assessment features the key marketed products consisting of MabThera/Rituxan (rituximab), Avastin (bevacizumab), Herceptin (trastuzumab), Revlimid (lenalidomide), Opdivo (nivolumab), Xtandi (enzalutamide), Gleevec/Glivec (imatinib mesylate), Alimta (pemetrexed) and Zytiga (abiraterone acetate). Similarly, the key pipeline products discussed are Durvalumab – AstraZeneca, Durvalumab and Tremelimumab – AstraZeneca, Abemaciclib - Eli Lilly, Rova-T (rovalpituzumab tesirine) – AbbVie, Neratinib - Puma Biotechnology, Acalabrutinib – AstraZeneca, KTE-C19 (Axicabtagene Ciloleucel)- Kite Pharma, and Tisagenlecleucel-T – Novartis.
The last section forecasts the market till 2023 and discusses the overall market size, generic penetration in the market, and forecast revenue by molecular type. Finally, the related companies enclosed in the report analyzed by revenue and market share are Roche, Celgene, Novartis, Bristol-Myers Squibb, Pfizer, and AstraZeneca.
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
